Modified Vaccinia Ankara attachment factors

Modified Vaccinia Ankara (MVA) is a highly attenuated strain of the vaccinia virus, widely utilized as a viral vector for vaccines and gene therapy. The infection process begins with the attachment of MVA virions to the host cell surface, a step mediated by attachment factors rather than a single high-affinity receptor (Schmidt et al., 2012). These factors primarily consist of cell-surface glycosaminoglycans, such as heparan sulfate and chondroitin sulfate, which interact with specific viral proteins like A27, H3, and D8 (Volz & Sutter, 2017). This initial docking facilitates the subsequent recruitment of the viral Entry Fusion Complex (EFC) to mediate membrane fusion. Because the term Human cells expressing attachment factors describes a cellular state or population rather than a discrete molecular entity, it is not classified as a standard therapeutic target in a pharmacological sense. While drugs like heparin can competitively inhibit this interaction in research settings, the broad physiological roles of these attachment factors present significant challenges for therapeutic targeting (Chung et al., 1998). However, the underlying attachment factors remain critical for understanding viral tropism and optimizing the delivery of MVA-based therapeutics.

Other names

MVA entry factorsVaccinia virus attachment receptorsHeparan sulfate proteoglycansChondroitin sulfateMVA-AF

Competitive inhibition of viral surface proteins (e.g., A27, D8) to prevent binding to host cell glycosaminoglycans.